SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 145 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $397,000 | -20.6% | 22,844 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $500,000 | +14.4% | 22,844 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $437,000 | +45.2% | 22,844 | +30.2% | 0.00% | +100.0% |
| Q2 2021 | $301,000 | +32.6% | 17,544 | +14.0% | 0.00% | 0.0% |
| Q3 2020 | $227,000 | -68.7% | 15,392 | -68.6% | 0.00% | -66.7% |
| Q2 2020 | $726,000 | +122.7% | 49,020 | +64.9% | 0.00% | +50.0% |
| Q1 2020 | $326,000 | -33.7% | 29,720 | -57.6% | 0.00% | -33.3% |
| Q2 2018 | $492,000 | +163.1% | 70,140 | +433.3% | 0.00% | +200.0% |
| Q1 2018 | $187,000 | -58.5% | 13,152 | -74.4% | 0.00% | -50.0% |
| Q4 2017 | $451,000 | +176.7% | 51,439 | +270.3% | 0.00% | +100.0% |
| Q3 2017 | $163,000 | – | 13,890 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |